Search the Newsreel

Humana Earnings Face High Expectations as Medicare Advantage Recovers

Humana reports earnings Wednesday after its stock surged this year on improving confidence in Medicare Advantage insurers. Investors will be watching medical costs and the company’s outlook. Continue Reading

Humana: Q2 Earnings Snapshot

Humana Inc. reported strong second-quarter earnings, with net income of $694 million, or $5.73 per share, adjusted to $7.61 per share. These results surpassed Wall Street expectations, which had estimated $6.22 per share. The health insurer also exceeded revenue forecasts, posting $40.87 billion, and …

Humana Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Humana Inc. (HUM) stock rose 1.98% on Tuesday, ending a four-day losing streak, despite the S&P 500 and Dow Jones Industrial Average also seeing gains. The stock's performance still underperformed compared to its competitors. This market update was automatically generated with data from Dow …

Humana Q2 2026 Earnings Preview

* Humana (HUM [https://seekingalpha.com/symbol/HUM]) is scheduled to announce Q2 earnings results on Wednesday, July 29th, before market open. * The consensus EPS estimate is $7.00 [https://seekingalpha.com/symbol/HUM/earnings/estimates] (+11.6% Y/Y) and the consensus revenue estimate is $40.57B (+25.3% Y/Y). * Over the last 2 years, HUM …

Humana study suggests Medicare Advantage payments may be less affected

A new study by Humana Healthcare Research indicates that favorable selection in Medicare Advantage (MA) is substantially lower than previous estimates, potentially leading to a smaller impact on MA payments. The research, published in Health Affairs Scholar, found that using comprehensive encounter data and …

New Humana Healthcare Research Study Finds Favorable Selection in Medicare Advantage is Substantially Lower Than MedPAC Estimates

Published in Health Affairs Scholar, the study finds that a single methodological refinement reduces favorable selection estimates by 42%-65%, suggesting a smaller impact on MA payments than previous analyses have indicated LOUISVILLE, Ky., July 28, 2026--(BUSINESS WIRE)--A new study from Humana Healthcare Research (HHR), …

Gear Up for Humana (HUM) Q2 Earnings: Wall Street Estimates for Key Metrics

Wall Street analysts expect Humana (HUM) to post quarterly earnings of $6.22 per share in its upcoming report, which indicates a year-over-year decline of 0.8%. Revenues are expected to be $40.65 billion, up 25.5% from the year-ago quarter. The current level reflects an upward …

Humana (HUM) Reports Q2: Everything You Need To Know Ahead Of Earnings

Humana (HUM) Reports Q2: Everything You Need To Know Ahead Of Earnings Health insurance company Humana (NYSE:HUM) will be announcing earnings results this Wednesday before the bell. Here's what you need to know. Humana met analysts' revenue expectations last quarter, reporting revenues of $39.65 …

Humacyte Inc Lobbyists, 2024

This OpenSecrets.org page details the lobbying activities of Humacyte Inc for 2024, identifying seven lobbyists, three of whom are "revolving door" lobbyists with previous federal government experience. The company spent $100,000 on lobbying in 2024, with G2G Consulting employing six lobbyists and DLA Piper …

The Zacks Analyst Blog Highlights CVS Health, Cardinal Health, Humana and ACADIA Pharmaceuticals

For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …

Humacyte, Inc. Revenue Breakdown – NASDAQ:HUMAW

Humacyte, Inc. (NASDAQ:HUMAW) generated $2.04 million in revenue last year, primarily from its Acellular Human Tissues segment. This represents an increase from $1.56 million in the previous year. The United States was the primary source of this revenue, accounting for the entire $2.04 million.

Ihuman Inc (IH) Institutional Confidence

This article provides an "Institutional Confidence" score for Ihuman Inc (IH) from TradingKey, noting a previous score of 3.00 with no change, updated on July 27, 2026. It lists key institutional shareholders and their recent activity (share holdings and percentage change), highlighting changes such …

Humana Inc Agencies, 2024

This OpenSecrets.org page details the federal agencies that Humana Inc. listed in its lobbying filings for 2024. The healthcare company named 10 different federal entities, including both executive branches like the Centers for Medicare & Medicaid Services and legislative bodies such as the U.S. …

Cash flow from operating activities of Humana Inc. – HAM:HUM

This article focuses on the cash flow from operating activities of Humana Inc. (HAM:HUM), listed on the Hamburg Stock Exchange. It indicates that the market is currently closed with no trades. The information is presented within the financial section of a trading platform, suggesting …

Net income before discontinued operations of Humana Inc. – HAM:HUM

This article focuses on the net income before discontinued operations for Humana Inc. (HUM) on the Hamburg Stock Exchange. The content appears to be a financial data page from TradingView, indicating that the market is closed with no trades recorded. The page provides a …

Ihuman Inc (IH) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for Ihuman Inc (IH). It indicates that the company has distributed a total of $0.00 in dividends over the past 5 years and currently shows no upcoming dividend data. The page also presents basic stock information …

Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings

The article details the shareholder structure of Humacyte Inc (HUMA), listing major institutional shareholders and their proportional holdings. It also provides a breakdown of shareholder types and historical institutional shareholding data from Q1 2023 to Q1 2026, alongside information on related ETFs.

Lawsuit against Humana moves forward over alleged misleading cost statements, stock dropped 22% in 2024

A securities fraud lawsuit against Humana Inc. and its former CEO and CFO is progressing, with a judge validating key claims. The lawsuit alleges that Humana misled investors about rising healthcare utilization costs between July 2022 and October 2024, leading to an inflated stock …

Humana Inc. (NYSE: HUM) Investor Reminder: Schubert Jonckheer Investigating Possible False Statements Following 22% Stock Drop

Schubert Jonckheer & Kolbe LLP is investigating potential legal claims against Humana Inc. (HUM) for alleged false and misleading statements regarding the company's exposure to increased healthcare utilization costs, which led to a 22% stock drop. A U.S. District Judge ruled that key claims …

Maharah Human Resources Co. Revenue Breakdown – TADAWUL:1831

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

Humacyte has announced that the FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The company plans to initiate a Phase 2a study in ten adult …

Humacyte Plans First Human Study of Bioengineered Vessel in Heart Bypass

Humacyte (Nasdaq: HUMA) has received FDA acceptance for its Investigational New Drug (IND) application, paving the way for a first-in-human Phase 2a clinical study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The study, expected to enroll ten adult …

Bronstein, Gewirtz & Grossman, LLC Encourages Humana Inc. (HUM) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Humana Inc. (HUM) regarding potential corporate wrongdoing. The firm is encouraging Humana stockholders who purchased securities before June 27, 2022, and still hold them, to contact them to assist with the investigation. The firm …

Humacyte Says US FDA Accepted IND for Human Trial of Coronary Tissue Engineered Vessel in Surgery

Humacyte, Inc. announced that the US FDA has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of its Coronary Tissue Engineered Vessel (CTEV). This study will evaluate the CTEV for use in Coronary Artery Bypass Grafting (CABG) surgery. The company …

Caxton Associates LLP Makes New Investment in Humana Inc. $HUM

Caxton Associates LLP has acquired a new stake in Humana Inc. by purchasing 5,646 shares worth approximately $979,000 in the first quarter. Several other institutional investors, including State of Wyoming, Kopernik Global Investors LLC, and Westpac Banking Corp, also adjusted their positions in Humana. …

Bank of Nova Scotia Sells 308,864 Shares of Humana Inc. $HUM

Bank of Nova Scotia significantly reduced its stake in Humana Inc. by selling 308,864 shares, decreasing its position by 85.6% in the first quarter. Despite this, other institutional investors have increased their holdings. Humana reported strong Q1 earnings, beating analyst estimates, and has received …

Stocks to Watch Today: Waaree Renewable, Authum Investment, Lodha Developers, Bank of Baroda, NTPC, AU...

IH|Ihuman Inc|Price:1.335|Chg%:-0.045

This article provides a company profile for iHuman Inc (IH), detailing its engagement in tech-powered educational products for children, including interactive apps and offline materials. It lists key company information such as its CEO, IPO date, and executive team. The article also touches upon …

iHuman Inc. Revenue Breakdown – NYSE:IH

This article provides a revenue breakdown for iHuman Inc. (NYSE:IH), highlighting that the majority of its revenue comes from China. In the last year, China contributed $112.27 million USD, which was a decrease from $128.14 million USD the previous year. The information is sourced …

Ihuman Inc (IH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The TradingKey report focuses on Ihuman Inc (IH) and its revenue breakdown, specifically noting that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company for the fiscal years available (FY2019-FY2024). It highlights that Ihuman …

Weiss Asset Management LP Buys 12,685 Shares of Humana Inc. $HUM

Weiss Asset Management LP increased its stake in Humana Inc. by 45% in the first quarter, purchasing an additional 12,685 shares, bringing their total holdings to 40,891 shares valued at approximately $7.09 million. The increase follows Humana's strong quarterly results, where it exceeded EPS …

Healthcare of Ontario Pension Plan Trust Fund Raises Stock Position in Humana Inc. $HUM

Healthcare of Ontario Pension Plan Trust Fund significantly increased its stake in Humana Inc. by 3,350.6% in the first quarter, now owning 336,572 shares valued at $58,358,000. Other institutional investors like Vanguard Group Inc., Capital International Investors, Pzena Investment Management LLC, State Street Corp, …

HUMA|Humacyte Inc|Price:0.625|Chg%:-0.014

Humacyte Inc. (HUMA) is a biotechnology company developing universally implantable bioengineered human tissues. The company is in late-stage clinical trials for vascular applications like hemodialysis and peripheral artery disease, and also has preclinical development in other areas. Trading at $0.625, the article provides an …

Ihuman Inc (IH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Ihuman Inc (IH), listing major institutional shareholders such as Morgan Stanley, Citadel Advisors, and Acadian Asset Management, along with their respective holdings and proportions. It also presents a historical overview of institutional shareholding from 2023Q4 to 2026Q1, …

Price to sales forward of Humacyte, Inc. – NASDAQ:HUMAW

This article from TradingView provides financial information for Humacyte, Inc. (NASDAQ: HUMAW), specifically focusing on its price-to-sales forward metric. The content highlights a specific period, value, and change percentage for this financial indicator, framed within a market data and analysis platform context.

Ihuman Inc (IH) Cash Flow

This article provides an overview of Ihuman Inc's cash flow statement, detailing its operating, investing, and financing cash flows. It highlights that Ihuman Inc generated $7.44M in operating cash flow in fiscal 2025 and spent $710.79K on capital expenditures in the most recent quarter. …